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Summary
 
A cytotoxic cycle triggered by DNA single-strand breakage and poly (ADP-ribose) synthetase
activation has been shown to contribute to the cellular injury during various forms of oxidant
stress in vitro. The aim of this study was to investigate the role of poly (ADP-ribose) synthetase
(PARS) in the process of neutrophil recruitment and in development of local and systemic in-
flammation. In pharmacological studies, PARS was inhibited by 3-aminobenzamide (10–20
mg/kg) in rats and mice. In other sets of studies, inflammatory responses in PARS
 
2
 
/
 
2
 
 mice
were compared with the responses in corresponding wild-type controls. Inhibition of PARS
reduced neutrophil recruitment and reduced the extent of edema in zymosan- and carra-
geenan-triggered models of local inflammation. Moreover, inhibition of PARS prevented neu-
trophil recruitment, and reduced organ injury in rodent models of inflammation and multiple
organ failure elicited by intraperitoneal injection of zymosan. Inhibition of PARS also reduced
the extent of neutrophil emigration across murine mesenteric postcapillary venules. This re-
duction was due to an increased rate of adherent neutrophil detachment from the endothelium,
promoting their reentry into the circulation. Taken together, our results demonstrate that
PARS inhibition reduces local and systemic inflammation. Part of the antiinflammatory effects
of PARS inhibition is due to reduced neutrophil recruitment, which may be related to main-
tained endothelial integrity.
 
I
 
n vitro studies have demonstrated that oxidative injury in
various cell types is related in part to DNA single-strand
breakage and the consequent activation of the nuclear en-
zyme poly (ADP-ribose) synthetase (PARS).
 
1
 
 Massive ADP
ribosylation of nuclear proteins by PARS then results in cel-
lular energy depletion and injury (1–6).
This present work was designed to elucidate (
 
a
 
) whether
inhibition of PARS exerts antiinflammatory effects in various
models of local and systemic inflammation, and (
 
b
 
) whether
inhibition of PARS affects neutrophil recruitment during
inflammation. In our studies we used 3-aminobenzamide, a
prototypical pharmacological inhibitor of PARS (1–7), and
genetically engineered mice lacking functional PARS en-
zyme (PARS
 
2
 
/
 
2
 
) (8).
 
Materials and Methods
 
Animals.
 
Male Swiss Albino mice (20–22 g; Interfauna,
Huntingdon, United Kingdom) were used for investigation of
the effect of 3-aminobenzamide in the zymosan peritonitis
model, and in leukocyte–endothelium interaction by intravital
microscopy.
Male Wistar rats (300–320 g; Charles River Laboratories,
Wilmington, MA) were used for investigation of the role of
PARS in the pathogenesis of the carrageenan-induced paw
edema, and in zymosan-induced multiple organ failure.
Responses in PARS
 
2
 
/
 
2
 
 and PARS
 
1
 
/
 
1
 
 mice (8) (129/Sv 
 
3
 
C57BL6, 20–22 g, kind gifts of Dr. Z.Q. Wang, Institute of Mo-
lecular Pathology, Vienna, Austria) were compared to assess the
role of PARS in the pathogenesis of the zymosan-induced multi-
ple organ failure in mice.
 
Zymosan-induced Peritonitis in Mice Treated with 3-aminobenz-
amide.
 
Peritonitis was induced by intraperitoneal injection of
zymosan (12.5 mg/kg) in 0.5 ml PBS (0.1 M, pH 7.4) (9). At 2 or
4 h, animals were killed by CO
 
2
 
 exposure, and peritoneal cavities
were washed with 3 ml of PBS containing 3 mM EDTA. Ali-
quots of the lavage fluids were then stained with Turk’s solution,
 
1
 
Abbreviations used in this paper:
 
 AST, aspartate aminotransferase; LDH,
lactate dehydrogenase; MPO, myeloperoxidase; PARS, poly (ADP-ribose)
synthetase.
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and differential counting was performed using a hematocytometer
and a light microscope. Data are reported as 10
 
6
 
 PMN per mouse.
The large predominance (
 
.
 
98%) of neutrophils in the PMN pop-
ulation in 2- and 4-h lavage fluids was confirmed in cytospin
preparations stained with May-Grünwald and Giemsa. Lavage
fluids were then centrifuged at 400 
 
g
 
 for 10 min, and supernatants
stored at 
 
2
 
20
 
8
 
C before evaluation of 
 
b
 
-glucuronidase activity,
according to a published protocol (10).
3-Aminobenzamide was dissolved in saline, and was sonicated
at appropriate concentrations for injecting 100–150 
 
m
 
l per
mouse. In the first set of experiments, vehicle or 3-aminobenz-
amide (10 or 20 mg/kg) was given intravenously immediately be-
fore intraperitoneal administration of zymosan. In another set of
experiments, vehicle or the PARS inhibitor (2, 10, or 20 mg/kg)
was given intravenously 2 h after zymosan administration. In con-
trol experiments, 3-aminobenzoic acid, a structural analog of
3-aminobenzamide with no inhibitory effect on PARS (6), was
used at a dose of 10 mg/kg.
 
PMN Adhesion and Emigration in Mice Treated with 3-aminobenz-
amide.
 
Mice were fasted overnight before experimentation. An-
imals were injected intraperitoneally with 12.5 mg/kg zymosan
(in 0.5 ml sterile saline) or saline (controls), and were left at lib-
erty until the beginning of the experiment. 4 h later, mesenteries
were prepared as described (11). Mice were anesthetized with di-
azepam (60 
 
m
 
l subcutaneously) and Hypnorm
 
TM
 
 (30 
 
m
 
l intramus-
cularly; Janssen Pharmaceutical Ltd., Oxford, United Kingdom).
A tracheotomy was performed to facilitate breathing. Cautery in-
cisions were made along the abdominal region, and the mesen-
teric vascular bed was exteriorized and placed on a plexiglass stage
for viewing. The preparation was then mounted on an Axioskop
FS (Carl Zeiss, Inc., Welwyn Garden City, United Kingdom)
with a water immersion objective lens (
 
3
 
40; Carl Zeiss, Inc.) to
observe the microcirculation. The preparation was transillumi-
nated with a 12-V, 100-W halogen light source. Images were dis-
played and recorded for subsequent offline analysis. Mesenteries
were superfused with 37
 
8
 
C bicarbonate-buffered solution (g/liter:
NaCl 7.71, KCl 0.25, MgSO
 
4
 
 0.14, NaHCO
 
3
 
 1.51, and CaCl
 
2
 
0.22, pH 7.4, gassed with 5% CO
 
2
 
/95% N
 
2
 
). One to three ran-
domly selected postcapillary venules (diameter between 20–40
 
m
 
m, length of at least 100 
 
m
 
m) were observed for each mouse.
Adhesion was monitored by counting, for each vessel, the num-
ber of adherent leukocytes in a 100-
 
m
 
m length. Leucocyte emi-
gration from the microcirculation into the tissue was quantified
by counting the number of cells that had emigrated out of the
vessel up to 50 
 
m
 
m away from the vessel wall in parallel with the
100-
 
m
 
m vessel segment.
In the first set of experiments, vehicle or 3-aminobenzamide
was given intravenously immediately before intraperitoneal ad-
ministration of zymosan. In a separate set of experiments, mesen-
teries were exposed 2 h after zymosan injection as described
above, and vessels with a congruous number of adherent leuko-
cytes (five to eight per branch) were chosen. Either PBS (100 
 
m
 
l)
or 3-aminobenzamide (20 mg/kg) was given intravenously
through the tail vein, and the fate of the adherent leukocytes was
monitored for 10 min.
 
Carrageenan-induced Paw Edema in Rats Treated with 3-aminobenz-
amide.
 
Rats received a subplantar injection 0.1 ml saline containing
1% 
 
l
 
-carrageenan into the right hind paw (12). The phlogogenic
agent was given together with vehicle, with 3-aminobenzamide,
or with the inactive structural analogue 3-aminobenzoic acid (25
 
m
 
g/paw). The test agents were solubilized in saline solution, and
the injection volume was 0.1 ml. Control animals received the
same volume of vehicle. The volume of the paw was measured
by a plethysmometer (Kent Laboratories, Kent, WA) (12).
Myeloperoxidase (MPO) activity, an index of PMN accumu-
lation, was determined as previously described (13). Paw tissues,
collected at the specified time, were homogenized in a solution
containing 0.5% hexadecyltrimethylammonium bromide dis-
solved in 10 mM potassium phosphate buffer (pH 7.0), and were
centrifuged for 30 min at 20,000 
 
g
 
 at 4
 
8
 
C. An aliquot of the su-
pernatant was then allowed to react with a solution of tetrameth-
ylbenzidine (1.6 mM) and 0.1 mM H
 
2
 
O
 
2
 
. The rate of change in
absorbance was measured by a spectrophotometer at 650 nm.
Myeloperoxidase activity was defined as the quantity of enzyme
degrading 1 
 
m
 
mol of peroxide/min at 37
 
8
 
C, and was expressed in
milliunits per 100 mg wt of wet tissue.
 
Zymosan-induced Peritonitis and Multiple Organ Failure in Rats
and Mice.
 
Rats or mice were injected with 500 mg/kg zymosan
i.p to induce multiple organ failure (14). 18 h after zymosan in-
jection, animals were killed by CO
 
2
 
 exposure. Plasma samples
were taken, and lactate dehydrogenase (LDH) levels and serum
aspartate aminotransferase (AST) levels were determined by a
clinical laboratory. The abdomen was carefully opened, and the
peritoneal cavity was washed with 2 ml of saline solution with
heparin (5 U/ml) and indomethacin (10 
 
m
 
g/ml).
Lavage fluids were then collected and measured, and exudate
values were obtained after subtracting the volume injected. Dif-
ferential cell counts were determined as described above. Lung,
liver, and small intestinal MPO activities were determined as de-
scribed for the paw tissues. For histopathological examination, tis-
sues were fixed in 10% neutral-buffered formaldehyde for 5 d,
embedded in paraffin, and sectioned. The sections were stained
with hematoxylin and eosin.
The above experiments were performed in rats and mice. In
rats, responses in vehicle-pretreated animals and responses in ani-
mals pretreated with 3-aminobenzamide (10 mg/kg, 10 min be-
fore zymosan and every 6 h thereafter) were compared. In mice,
responses in PARS
 
2
 
/
 
2
 
 and PARS
 
1
 
/
 
1
 
 animals were compared.
 
Data Analysis.
 
All values in the figures and text are expressed
as mean 
 
6
 
 standard error of the mean of 
 
n
 
 observations, where 
 
n
 
represents the number of animals studied. Data sets were exam-
ined by one- and two-way analysis of variance, and individual
group means were compared with Student’s unpaired 
 
t
 
 test. Non-
parametric data were analyzed with the Fisher’s exact test. A 
 
P
 
value 
 
,
 
0.05 was considered significant.
 
Results
 
3-Aminobenzamide Reduces the Local Inflammatory Response
in the Zymosan Peritonitis Model.
 
Zymosan injection into mu-
rine peritoneal cavities produced a time-dependent PMN
accumulation that was maximal at 4 h (15). Pretreatment of
animals with 3-aminobenzamide (10–20 mg/kg) resulted in
a significant reduction of PMN accumulation (Fig. 1 
 
A
 
).
The PARS inhibitor did not modify the extent of cell acti-
vation at the inflammatory site, assessed as 
 
b
 
-glucuronidase
activity in the lavage fluids. For instance, 
 
b
 
-glucuronidase
activity was 66 
 
6
 
 8 and 58 
 
6
 
 17 U per 10
 
6
 
 PMN in the
presence of PBS and 3-aminobenzamide (20 mg/kg) treat-
ment, respectively (
 
n
 
 
 
5
 
 6). The inhibitory action of 3-ami-
nobenzamide on PMN elicitation was not the result of an
indirect effect on the number of circulating leukocytes,
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since 3-aminobenzamide did not significantly alter the pro-
file of circulating blood cells (Table 1). The inactive struc-
tural analog of 3-aminobenzamide, 3-aminobenzoic acid,
did not alter PMN recruitment (Fig. 1).
Fig. 1 
 
B
 
 shows the effect of 3-aminobenzamide treat-
ment (given 2 h after zymosan) on the number of cells re-
covered from the peritoneal cavities at the 4-h time point.
In the period between 2 and 4 h, PMNs accumulated in re-
sponse to zymosan with a high rate of influx (
 
z
 
3.5 
 
3
 
 10
 
6
 
cells/h), and administration of 3-aminobenzamide was
highly effective in reducing cell recruitment. More than
70% reduction in PMN influx was seen with 10 or 20 mg/
kg 3-aminobenzamide, whereas the PARS inhibitor was
inactive at 2 mg/kg (Fig. 1 
 
B
 
).
 
3-Aminobenzamide Inhibits PMN Emigration Across Mouse
Mesenteric Postcapillary Venules Challenged with Zymosan.
 
The effect of 3-aminobenzamide on leukocyte–endothelial
interaction was monitored by intravital microscopy. Zymo-
san injection induced high numbers of adherent and emi-
grated leukocytes in mouse mesenteric postcapillary venules
4 h after administration (Fig. 2). Treatment of mice with
3-aminobenzamide (20 mg/kg) immediately before zymo-
san did not modify the extent of cell adhesion (Fig. 2 
 
A
 
),
but significantly reduced the number of cells that emigrated
outside the postcapillary venules (Fig. 2 
 
B
 
).
We then investigated the fate of the adherent leukocytes
in the presence or absence of pharmacological inhibition of
PARS in the mesenteries inflamed with zymosan. Postcap-
illary venules were visualized 2 h after zymosan injection.
Subsequently, vehicle or 3-aminobenzamide (20 mg/kg)
was given intravenously. While most of the adherent cells
emigrated through the endothelium of the postcapillary
venules in the vehicle-treated animals, a large majority de-
tached from the endothelial surface after treatment with the
PARS inhibitor (Fig. 3 
 
A
 
). In vehicle treated-mice, only
25% of adherent cells detached after vehicle injection,
whereas most leukocytes emigrated (Fig. 3 
 
B
 
). In contrast,
in response to treatment with 3-aminobenzamide, cells
continued to detach and reenter the circulation. A total of
80% of adherent cells detached after administration of the
PARS inhibitor (Fig. 3 
 
B
 
).
Although 3-aminobenzamide did not apparently modify
zymosan-induced cell adhesion at a fixed time point, it in-
creased the rate of cell detachment from the postcapillary
venule endothelium. In this protocol, only the fate of cells
that were adherent before 3-aminobenzamide or vehicle
intravenous challenge was followed, without considering
newly adhered cells. The two processes (adhesion and de-
tachment) equilibrated themselves, explaining why no dif-
ference in the degree of cell adhesion was seen at a single
time point. Nonetheless, following the fate of adherent
cells immediately after 3-aminobenzamide administration
permitted identification of the process that was selectively
Figure 1. 3-aminobenzamide inhibits PMN accumulation in murine
peritoneal cavities in response to zymosan challenge. (A) Mice received
various intravenous doses of 3-aminobenzamide (3-AB, 10 or 20 mg/kg)
or its inactive structural analogue 3-aminobenzoic acid (3-ABA, 10 mg/
kg) immediately before the intraperitoneal administration of zymosan
(12.5 mg/kg). Peritoneal cavities were washed 4 h later, and the number
of PMN in the lavage fluids was quantified. Data are mean 6 SEM of 6–12
mice per group. *P ,0.05 vs. control group (treated with vehicle). (B)
Mice were treated with zymosan (1 mg intraperitoneally) at time 0. Vari-
ous doses of 3-aminobenzamide were given intravenously 2 h later, and
the number of PMN accumulated into peritoneal cavities was quantified
4 h after zymosan. Some mice were killed 2 h after zymosan administra-
tion. Data are mean 6 SEM of 8–14 mice per group. *P ,0.05 vs. con-
trol group (dose 0).
 
Table 1.
 
Lack of Effect of 3-aminobenzamide on Circulating Peripheral Blood Leukocyte Numbers
 
Treatment PMN Monocytes Lymphocytes
 
10
 
6
 
/ml % 10
 
6
 
/ml % 10
 
6
 
/ml %
 
PBS 0.86 
 
6 0.21 (10.4) 1.00 6 0.21 (13.2) 5.90 6 0.87 (76.4)
3-aminobenzamide 0.92 6 0.06 (14.2) 1.03 6 0.24 (15.3) 4.82 6 0.59 (70.5)
Mice received either PBS (100 ml i.v.) or 3-aminobenzamide (20 mg/kg i.v.) 4 h before blood colllection by cardiac puncture. Differential leuko-
cyte counting was performed after staining in Turk’s solution. Data are mean 6 SEM of six mice per group.
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affected by the drug. The net result is a diminished cell em-
igration across postcapillary venules and reduced PMN tis-
sue infiltration.
3-Aminobenzamide Reduces Carrageenan-induced Rat Paw
Edema. Based on the marked effects of 3-aminobenzamide
on neutrophil recruitment in the zymosan-induced models
of inflammation, we investigated the potential antiinflam-
matory effect of this PARS inhibitor in experimental mod-
els of inflammation where neutrophil recruitment plays a
crucial role. One of these processes is the carrageenan-
induced local inflammation and tissue injury (16, 17). In
the carrageenan-induced rat paw edema model, pretreat-
ment of the animals with 3-aminobenzamide (25 mg/paw)
caused a marked reduction in edema development (Fig. 4
A), and significantly reduced the increase in tissue levels of
myeloperoxidase, indicative of reduced neutrophil accu-
mulation in the paw (Fig. 4 B). The degree of inhibition by
3-aminobenzamide of the paw edema was less pronounced
(,50% inhibition) at 1–2 h, but it was more pronounced at
4 h (.75% inhibition). This difference in the degree of in-
hibition may be related to the nature of the various media-
tors involved in the pathogenesis of carrageenan-induced
paw edema. In the early stage, endogenous amines and
prostaglandins play an important role, while infiltrating
PMNs play a crucial role in the more delayed injury (3–4 h)
(12, 16–18). Nevertheless, peroxynitrite production, formed
by the reaction of superoxide with NO (the latter pro-
duced by constitutive NO synthase isoforms), is well estab-
lished, even in the early phase of inflammation in this
model (19, 20). Similar to the results of the zymosan peri-
tonitis studies, the inactive structural analog of 3-aminobenz-
amide, 3-aminobenzoic acid, did not alter the development
of paw edema (n 5 5, data not shown).
3-Aminobenzamide and PARS2/2 Phenotype Reduce the
Systemic Inflammation (Multiple Organ Failure) Induced by Zy-
mosan. Intraperitoneal injection of a high dose of zymo-
san induces nonseptic shock and multiple organ failure, with
intensive PMN migration into various organs (14, 21–23).
In our experiments we chose the 18-h time point, and ob-
served strong peritoneal inflammation (detected as exuda-
tion and leukocyte accumulation) and increased PMN in-
filtration into various organs (Fig. 5). In the wild-type
(PARS1/1) control mice, zymosan injection increased se-
Figure 2. 3-aminobenzamide inhibits cell emigration across murine
mesenteric postcapillary venules. Mice received 3-aminobenzamide (20
mg/kg i.v.) or PBS (0.1 ml i.v.) immediately before administration of zy-
mosan (1 mg i.p.). Control mice received sterile saline (0.5 ml i.p.). The
mesenteries were observed 4 h later (1–3 vessels were analyzed for each
animal) quantifying the number of adherent leukocytes per 100 mm vessel
length (A) and the number of leukocytes emigrated outside postcapillary
venules up to 50 mm from the vessel wall (B). Values are mean 6 SEM of
six mice per group. *P ,0.05 vs. zymosan alone.
Figure 3. Kinetics of cell detachment from postcapillary venules. (A)
Number of adherent cells after administration of 3-aminobenzamide or
vehicle. Mice were administered intraperitoneally with zymosan (1 mg) 2 h
before exposure of mesenteric microcirculation. Vessels with at least five
adherent cells were chosen, and either 3-aminobenzamide (20 mg/kg) or
PBS (0.1 ml) were given intravenously (time 0). The fate of leukocytes
was monitored further for 10 min, recording the number of cells remain-
ing adhered at 2-min intervals. Data are obtained from five mice per
group. *P ,0.05 vs. vehicle. (B) The fate of adherent leukocytes in
mouse mesenteric postcapillary venules challenged with zymosan after ve-
hicle or 3-aminobenzamide treatment. Mesenteric postcapillary venules
were exposed 2 h after zymosan injection (1 mg i.p.) and proper vessels
were chosen (with 5–8 adherent cells). After a 10-min stabilization pe-
riod, PBS (100 ml) or 3-aminobenzamide (20 mg/kg) were administered
intravenously by the tail vein. The fate of the adherent leukocytes within
the postcapillary venules was then monitored for 10 min. Data are ob-
tained from five mice per group. *P ,0.05 vs. vehicle (Fisher’s exact test).
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rum AST and LDH levels to 170 6 25 and 137 6 24% of
control, respectively (P ,0.05; n 5 5). Treatment of rats
with 3-aminobenzamide (10 mg/kg), or the absence of
PARS in mice (animals with the PARS2/2 genotype) re-
sulted in a pronounced reduction of exudate volumes and
leukocyte counts in the peritoneum, and significantly at-
tenuated the zymosan-induced increase in the MPO activ-
ity in the organs studied (Fig. 5). There were no significant
increases in serum AST and LDH levels in the PARS2/2
mice in response to zymosan injection (respective values
were 72 6 20% and 97 6 32% of control; n 5 5). There
was also a marked reduction in the degree of histological
injury in the PARS2/2 mice after zymosan injection when
compared with the response to zymosan in the PARS1/1
mice. The extent of zymosan-induced mononuclear cell
infiltration and the degree of the histological damage were
markedly reduced in the lung (Fig. 6) and liver (not shown)
of the PARS2/2 mice when compared with the wild-type
PARS1/1 control mice.
Discussion
PARS Inhibition Reduces PMN Accumulation in Inflamma-
tion. The main finding of this study is that PARS inhibi-
tion (by a pharmacological approach or by the use of ge-
netically engineered animals) reduces PMN recruitment
and accumulation into inflammatory tissue sites. Extrava-
sated PMNs become activated once in the inflammatory
sites, secreting a variety of substances such as growth fac-
tors, chemokines and cytokines, complement components,
proteases, NO, reactive oxygen metabolites, and peroxyni-
trite, all important mediators of tissue injury (24–26). Pre-
Figure 4. Effects of 3-aminobenzamide in the carrageenan-induced
paw edema model. (A) Changes in paw volume in rat paws injected with
0.1 ml carrageenan (1% wt:vol) alone or with 25 mg 3-aminobenzamide.
(B) Myeloperoxidase (MPO) activity 3 h after carrageenan injection: ef-
fect of vehicle or 3-aminobenzamide (25 mg) treatment. Data are mean 6
SEM of six to eight animals in each group; ##P ,0.01 represents signifi-
cant reduction in paw volume or MPO activity in the 3-aminobenzamide–
treated group.
Figure 5. Effects of PARS inhibition on the course of the zymosan-induced
multiple organ failure in rats (A–C) and mice (D–E). Data represent values 18 h
after vehicle (V) or zymosan (Z) administration (500 mg/kg i.p. for 18 h). (A
and D) Exudate volumes; (B and E) PMN counts in the exudate; (C and F)
MPO activities in lung, liver, and small intestine. In rats, PARS was inhibited
by treatment with 3-aminobenzamide (10 mg/kg i.v. 10 min before zy-
mosan administration, and was repeated every 6 h). In mice, responses in
PARS1/1 wild-type controls and PARS2/2 animals were compared. Data
are mean 6 SEM of five to six animals in each group. **P ,0.01 represents
significant increase in exudate volume, cell number, or MPO activity in
the 3-aminobenzamide–treated group. ##P ,0.01 represents significant re-
duction of the various parameters in the group in which PARS was inhibited.
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vention of neutrophil-dependent inflammatory pathways is
likely to contribute to the reduced fluid extravasation and
improved histologic status after PARS inhibition. There
are recent reports from our laboratory and from other
groups showing the protective effect of PARS inhibitors in
experimental models of stroke (4, 27), endotoxic shock
(28), and ischemia-reperfusion injury (29). Because exten-
sive activation of PARS due to massive oxidant-mediated
DNA injury can lead to pronounced NAD1 and ATP de-
pletion in various tissues, it was generally assumed that the
mode of protection by inhibitors of PARS is directly re-
lated to improved metabolic status of the target tissues in
these models (1–6, 27, 28). In fact, in in vitro studies, our
group and other investigators have observed that hydrogen
peroxide, oxyradical- or peroxynitrite-induced cellular in-
jury is ameliorated by pharmacological inhibition of PARS
(1–6, 27, 28), or in cells derived from the PARS2/2 mice,
when compared to corresponding wild-type controls (6,
30). Based on the data presented in this study, however, we
propose that reduced neutrophil recruitment represents an
important additional mechanism for the antiinflammatory
effects provided by PARS inhibition.
Although PARS inhibition was effective in reducing
PMN recruitment in all inflammatory models tested, para-
doxically, the protective effects appeared to be more pro-
nounced in more severe forms and more delayed stages of
inflammation (compare, for example, the effects of 3-ami-
nobenzamide on the delayed versus the early phase of zy-
mosan peritonitis (Fig. 1) or carrageenan paw edema (Fig.
4). This effect may be related to the fact that PARS activa-
tion and related cellular alterations mainly occur under
conditions of more severe oxidant stress.
It is likely that inhibition of PARS exerts antiinflammatory
effects both independently of PMN accumulation and via
inhibition of PMN influx into the tissues. An example for a
PMN-independent protection is inhibition of paw edema de-
velopment in the early phase of carrageenan edema; 1–2 h
after carrageenan injection, only a small degree of PMN in-
filtration into the paw tissue can be detected (16–20). Such
early protection by PARS inhibitors may be related to pro-
tection against early, PMN-independent oxidant injury. A
likely species responsible for such effects is peroxynitrite, an
oxidant produced by the reaction of NO and superoxide
anion in this early stage of inflammation (19, 20). There is
Figure 6. Effects of PARS inhibition on the course of the zymosan-induced pulmonary injury mice. Representative lung sections from sham PARS1/1
(A) and PARS2/2 (B) mice demonstrating normal alveolar architecture. Lung sections from zymosan-treated PARS1/1 mice demonstrate interstitial
hemorrhage and mononuclear cell accumulation (arrows) (C). Lung sections from zymosan-treated PARS2/2 mice demonstrate reduced interstitial hem-
orrhage and a lesser cellular infiltration (D). Sections are representative of n 5 4 mice examined for each group.
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now good evidence that many cytotoxic effects of peroxy-
nitrite (suppression of cellular metabolism, epithelial hyper-
permeability, endothelial dysfunction) are at least in part
due to PARS activation (1–6, 28, 31).
The antineutrophil and antiinflammatory effects of 3-ami-
nobenzamide were likely to be related to PARS inhibition,
rather than some other pharmacological action of this agent,
since (a) the inactive analog of 3-aminobenzamide (3-ami-
nobenzoic acid) did not affect neutrophil recruitment or
edema formation, and (b) the antiinflammatory effects of
3-aminobenzamide were also reproducible in the PARS2/2
animals in the zymosan model of multiple organ failure.
With regards to 3-aminobenzoic acid, it is noteworthy that
in contrast to 3-aminobenzamide, 3-aminobenzoic acid does
not protect endothelial cells against oxidant injury (6), or
tissues against reperfusion injury (29).
PARS Modulates a Postadhesion Phenomenon. What, then,
is the mechanism of protection against PMN recruitment
provided by PARS inhibition? The data presented in this
study provide evidence that the effects of PARS inhibition
are mainly due to interference with PMN postadhesion
phenomena. The strongest indication for this conclusion
derives from our experiments using intravital microscopy,
which allows characterization of temporally related pro-
cesses such as rolling, adhesion, and emigration (32–35). In
our model, zymosan challenge produced a significant de-
gree of cell adhesion and emigration in the mouse mesen-
teric microcirculation. Treatment of mice with 3-ami-
nobenzamide did not modify zymosan-induced cell adhesion
to any extent, but the drug suppressed the degree of cell
emigration. This result clearly indicated that 3-aminoben-
zamide was affecting postadhesion phenomena such that
only the number of emigrated cells was altered when analy-
sis was done at a fixed time point (4 h). To further investi-
gate this phenomenon, an appropriate protocol was set up
to monitor the adherent leukocytes in real time. Inflamma-
tion in the mouse mesentery was induced by zymosan, and
postcapillary venules with a congruous number of adherent
cells were selected, such that their fate could be monitored
after intravenous challenge with 3-aminobenzamide or ve-
hicle. Under these conditions, the PARS inhibitor pro-
duced a marked phenomenon of detachment. A similar,
higher incidence of leukocyte detachment has been de-
scribed in response to dexamethasone (33).
The mechanisms regulating leukocyte emigration through
the gap formed between adjacent endothelial cells in in-
flammatory conditions are incompletely understood. In this
respect, adhesion molecules such as leukocyte integrins, as
well as endothelial intercellular adhesion molecule-1 and
platelet-endothelial cell adhesion molecule-1, have been
shown to play an important role (32, 34). Since PARS reg-
ulates the expression of various genes (36–38), the possibil-
ity that PARS may alter the expression of adhesion recep-
tors involved in postadhesion/emigration processes may be
proposed. The immediate course (within minutes) of the
leukocyte detachment seen after 3-aminobenzamide ad-
ministration, however, would argue against a mechanism
related to altered expression of adhesion molecules, at least
in this experimental setting. Endothelial-derived NO in-
hibits PMN infiltration into the inflammatory tissue sites.
In this respect, there are a number of reports demonstrating
that oxidant injury to the vascular endothelium, triggered
by oxyradicals or by peroxynitrite, is in part mediated by
PARS activation (6, 39). Inhibition of PARS has been
shown to improve the morphology, metabolic status, and
function of the vascular endothelium under oxidant stress
(6, 39). Thus, PARS may modulate PMN emigration by
altering the metabolic/functional status of the vascular en-
dothelium.
These data, coupled with a number of recent observa-
tions, suggest that PARS activation plays a role in oxidant
injury in various forms of inflammation and reperfusion in-
jury. These data emphasize the importance of neutrophil
recruitment blockade for the protection provided by PARS
inhibition. This effect, coupled with a direct cytoprotective
effect of PARS inhibition against oxidant injury (1–6, 28,
30, 39), may explain the antiinflammatory effects seen with
PARS inhibition. Based on these data, we propose that
pharmacological inhibition of PARS represents a novel
strategy for antiinflammatory therapy.
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